Can the presence of anemia on admission improve the predictive value of the GRACE risk score for short- and medium-term mortality after acute coronary syndrome?;Pode a presença de anemia na admissão melhorar a capacidade preditiva do score GRACE para mortalidade a curto e médio prazo após síndrome coronária aguda?

Revista Portuguesa de Cardiologia

Volumn 31, Issue 4, 2012, Pages 279-285

  Timóteo, Ana Teresa ^a   Hamad, Hamad ^a   Miranda, Fernando ^a   Santos, Ninel ^a   Oliveira, José Alberto ^a   Ferreira, Maria Lurdes ^a   Cruz Ferreira, Rui ^a  

^a HOSPITAL DE SANTA MARTA   (Portugal)

Author keywords

Acute coronary syndrome; Anemia; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ANEMIA; ANGIOPLASTY; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIVARIATE ANALYSIS; BLEEDING; CLINICAL EVALUATION; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE REGISTRY; FEMALE; GRACE RISK SCORE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PROGNOSIS; RISK; RISK FACTOR; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STRATIFIED SAMPLE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84862735768     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2011.12.015     Document Type: Article

References (21)

1. Arant CB, Wessel TR, Olson MB, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: Results from the National Heart, Lung, and Blood Institute women's ischemia syndrome evaluation study. J Am Coll Cardiol. 2004;43:2009-14.
2. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcome: insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 2003;107:223-5.
3. Keough-Ryan TM, Kiberd BA, Dipchard CS, et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis. 2005;46:845-55.
4. Voeltz MD, Patel AD, Feit F, et al. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary interventions. Am J Cardiol. 2007;99:1513-7.
5. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230-6.
6. Bindra K, Berry C, Rogers J, et al. Abnormal haemoglobin levels in acute coronary syndromes. QJM. 2006;99:851-62.
7. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042-9.
8. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003;163:2345-53.
9. Cockcroft DW, Gault MH. Predictors of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
10. World Health Organization. Nutritional anemias: report of a WHO scientific group. Geneva: World Health Organization; 1968.
11. Most AS, Ruocco Jr NA, Gewirtz H. Effect of a reduction in blood viscosity on maximal myocardial oxygen delivery distal to a moderate coronary stenosis. Circulation. 1986;74:1085-92.
12. Dauerman HL, Lessard D, Yarzebski J, et al. Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol. 2005;96:1379-83.
13. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary interventions: development and initial validation. J Am Coll Cardiol. 2004;44:1393-9.
14. Meneveau N, Schiele F, Seronde MF, et al. Anemia for risk assessment of patients with acute coronary syndromes. Am J Cardiol. 2009;103:442-7.
15. Maréchaux S, Barrailler S, Pinçon C, et al. Prognostic value of hemoglobin decline over the GRACE score in patients hospitalized for an acute coronary syndrome. Heart Vessels. 2012;27:119-27.
16. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial. Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142-54.
17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.
18. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436-43.
19. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
20. Schulman S, Kearon C, on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-4.
21. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials - proposal of a new classification. Am J Cardiol. 2007;99:288-90.